Premium
Subtherapeutic serum quetiapine concentrations after absorption inhibition by binding resins: a case report
Author(s) -
Hoge R. H. L.,
Arbouw M. E. L.,
Radstake S. D. W. S.,
Berlo – van de Laar I. R. F.
Publication year - 2015
Publication title -
journal of clinical pharmacy and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.622
H-Index - 73
eISSN - 1365-2710
pISSN - 0269-4727
DOI - 10.1111/jcpt.12265
Subject(s) - quetiapine , quetiapine fumarate , absorption (acoustics) , serum concentration , pharmacology , medicine , chromatography , chemistry , psychiatry , materials science , atypical antipsychotic , schizophrenia (object oriented programming) , antipsychotic , composite material
Summary What is known and objective Polystyrene sulfonate and sevelamer are binding resins that are used in the treatment of, respectively, hyperkalemia and hyperphosphatemia. It is unknown whether these resins interact with the antipsychotic quetiapine. Case summary We report on a woman with unexplainable low serum quetiapine concentrations who also used the binding resins polystyrene sulfonate and sevelamer. An In vitro binding assay showed binding of quetiapine by these resins. Separation of the ingestion times of quetiapine and the binding resins resulted in increased serum levels in this patient. What is new and conclusion Polystyrene sulfonate and sevelamer are able to bind quetiapine. Healthcare professionals should be aware of this potential drug–drug interaction as this could lead to antipsychotic treatment failure.